|
Cyplasin-SC™ kills melanoma cells, even derived from different patients, but leaves normal human cells unharmed Edmonton, Alberta, September 5, 2007 CYPL: OTCBB, Frankfurt Exchange WKN:XYIA It is well known that many cancer types – or even the same cancer in different patients – show different sensitivities to a given therapeutic treatment. In earlier studies Cyplasin-SC™ has shown to be an efficient killer of many cancer cell types whereas normal human cells were left intact. An independent third party study conducted by Professor di Liegro, Department of Medicine of the University of Palermo, Italy, tested Cyplasin-SC on 5 melanoma cell lines derived from 5 different patients to determine if all melanoma cells were equally susceptible to Cyplasin-SC or if there were specific melanomas that did not respond to the drug. As a control to these experiments normal human cells were also exposed to the same concentrations of Cyplasin-SC used for the melanoma experiments The results presented unequivocal evidence that all melanoma cell types studied were killed by Cyplasin-SC whereas even at the highest concentrations of Cyplasin-SC used in these experiments normal human cells remained unaffected. However, within this group of five different human melanomas, two were detected that required almost two times the dose that was sufficient to kill other melanomas. This corresponds exactly to the situation “in real life” where one patient reacts to low concentration of a given drug whereas others require higher doses for the same therapeutic effect. Yet, even such high doses were not harmful to normal human cells. These results confirm convincingly the usefulness of Cyplasin-SC as a treatment of melanoma. The required concentrations for killing the individual tumor can be efficiently optimized without harming normal cells, or in other words, the concentration window for individual therapy is large and separated enough from a concentration that may harm normal cells. These results will now be transferred to animal dose ranging studies and continue on to actual tumor-bearing animals. About Melanoma Market statistics for skin cancer and melanoma show that melanoma currently affects more then 2.4 million people worldwide. In the US more than 62,000 new cases are reported every year, as fair-skinned and sunbelt populations are at high risk for the disease. Australia has the highest rate of melanoma in the world among males and has the second highest rate in the world among females (Australia’s Health 2004, AIHW). Overall the world wide incidence has doubled over the past 20 years. About Cyplasin-SC™ Cyplasin-SC has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as a potential anti- cancer therapeutic product. Patents have been issued to the Company covering the Cyplasin-SC protein. About Cyplasin Biomedical Ltd. (CBL) Founded in 2007 and headquartered in Edmonton, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company’s current goal is to develop and commercialize the anticancer properties of Cyplasin-SC. CBL is publicly traded (CYPL:OTCBB) Forward-Looking Statements This Press release includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based without limitation, as statements regarding future drug development activities, anticipated products, or anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, such as market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time that may cause actual results or performance to differ materially from those currently anticipated in such statements. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Although Cyplasin Biomedical Ltd., believes that its expectations and the information in this Press release were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the Press release, and neither Cyplasin Biomedical nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in the Press release. The OTCBB Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. Contact: Garth Likes |